Rudolf Schicho1, Martin Storr. 1. Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Graz, Austria.
Abstract
BACKGROUND/AIMS: Compounds of Cannabis sativa are known to exert anti-inflammatory properties, some of them without inducing psychotropic side effects. Cannabidiol (CBD) is such a side effect-free phytocannabinoid that improves chemically induced colitis in rodents when given intraperitoneally. Here, we tested the possibility whether rectal and oral application of CBD would also ameliorate colonic inflammation, as these routes of application may represent a more appropriate way for delivering drugs in human colitis. METHODS: Colitis was induced in CD1 mice by trinitrobenzene sulfonic acid. Individual groups were either treated with CBD intraperitoneally (10 mg/kg), orally (20 mg/kg) or intrarectally (20 mg/kg). Colitis was evaluated by macroscopic scoring, histopathology and the myeloperoxidase (MPO) assay. RESULTS: Intraperitoneal treatment of mice with CBD led to improvement of colonic inflammation. Intrarectal treatment with CBD also led to a significant improvement of disease parameters and to a decrease in MPO activity while oral treatment, using the same dose as per rectum, had no ameliorating effect on colitis. CONCLUSION: The data of this study indicate that in addition to intraperitoneal application, intrarectal delivery of cannabinoids may represent a useful therapeutic administration route for the treatment of colonic inflammation.
BACKGROUND/AIMS: Compounds of Cannabis sativa are known to exert anti-inflammatory properties, some of them without inducing psychotropic side effects. Cannabidiol (CBD) is such a side effect-free phytocannabinoid that improves chemically induced colitis in rodents when given intraperitoneally. Here, we tested the possibility whether rectal and oral application of CBD would also ameliorate colonic inflammation, as these routes of application may represent a more appropriate way for delivering drugs in human colitis. METHODS: Colitis was induced in CD1 mice by trinitrobenzene sulfonic acid. Individual groups were either treated with CBD intraperitoneally (10 mg/kg), orally (20 mg/kg) or intrarectally (20 mg/kg). Colitis was evaluated by macroscopic scoring, histopathology and the myeloperoxidase (MPO) assay. RESULTS: Intraperitoneal treatment of mice with CBD led to improvement of colonic inflammation. Intrarectal treatment with CBD also led to a significant improvement of disease parameters and to a decrease in MPO activity while oral treatment, using the same dose as per rectum, had no ameliorating effect on colitis. CONCLUSION: The data of this study indicate that in addition to intraperitoneal application, intrarectal delivery of cannabinoids may represent a useful therapeutic administration route for the treatment of colonic inflammation.
Authors: Erin L Karschner; W David Darwin; Robert S Goodwin; Stephen Wright; Marilyn A Huestis Journal: Clin Chem Date: 2010-11-15 Impact factor: 8.327
Authors: Martin A Storr; Catherine M Keenan; Dominik Emmerdinger; Hong Zhang; Birol Yüce; Andrei Sibaev; Federico Massa; Nancy E Buckley; Beat Lutz; Burkhard Göke; Stephan Brand; Kamala D Patel; Keith A Sharkey Journal: J Mol Med (Berl) Date: 2008-05-21 Impact factor: 4.599
Authors: J M Cunha; E A Carlini; A E Pereira; O L Ramos; C Pimentel; R Gagliardi; W L Sanvito; N Lander; R Mechoulam Journal: Pharmacology Date: 1980 Impact factor: 2.547
Authors: B Romano; F Borrelli; I Fasolino; R Capasso; F Piscitelli; Mg Cascio; Rg Pertwee; D Coppola; L Vassallo; P Orlando; V Di Marzo; Aa Izzo Journal: Br J Pharmacol Date: 2013-05 Impact factor: 8.739
Authors: A Stančić; K Jandl; C Hasenöhrl; F Reichmann; G Marsche; R Schuligoi; A Heinemann; M Storr; R Schicho Journal: Neurogastroenterol Motil Date: 2015-07-30 Impact factor: 3.598
Authors: M Sałaga; A Mokrowiecka; P K Zakrzewski; A Cygankiewicz; E Leishman; M Sobczak; H Zatorski; E Małecka-Panas; R Kordek; M Storr; W M Krajewska; H B Bradshaw; J Fichna Journal: J Crohns Colitis Date: 2014-02-14 Impact factor: 9.071
Authors: Chris D Verrico; Shonda Wesson; Vanaja Konduri; Colby J Hofferek; Jonathan Vazquez-Perez; Emek Blair; Kenneth Dunner; Pedram Salimpour; William K Decker; Matthew M Halpert Journal: Pain Date: 2020-09-01 Impact factor: 7.926